Annamycin receives FDA orphan drug designation for soft tissue sarcomas

Annamycin, an anthracycline antibiotic, previously received orphan drug designation in the US for the treatment of relapsed or refractory acute myeloid leukaemia. It is now being researched in phase 1B/2 trials for use in soft tissue sarcomas.

Source:

Biospace Inc.